19:28 , Jul 3, 2018 |  BC Extra  |  Company News

Management tracks: Cigna, Novocure, Voyager

Health services company Cigna Corp. (NYSE:CI) appointed Mark McClellan to its board, effective the earlier of Dec. 1 or the close of Cigna's acquisition of Express Scripts Holding Co. (NASDAQ:ESRX). McClellan is director of the...
23:17 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

FDA approves Neos' Cotempla XR-ODT for ADHD

Last month, FDA approved an NDA from Neos Therapeutics Inc. (NASDAQ:NEOS) for Cotempla XR-ODT (methylphenidate XR-ODT) to treat ADHD in patients ages 6-17. The product is an extended-release oral disintegrating tablet formulation of methylphenidate using...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
22:43 , Jul 7, 2017 |  BioCentury  |  Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
18:26 , Jul 6, 2017 |  BC Week In Review  |  Financial News

Neos raises $32.4M in follow-on

On June 27, drug delivery company Neos Therapeutics Inc. (NASDAQ:NEOS) raised $32.4 million through the sale of about 4.8 million shares at $6.75 in a follow-on underwritten by Cantor Fitzgerald. Neos Therapeutics Inc. (NASDAQ:NEOS), Grand...
23:20 , Apr 7, 2017 |  BioCentury  |  Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...
20:41 , Feb 3, 2017 |  BC Week In Review  |  Financial News

Neos Therapeutics completes follow-on

On Feb. 3, drug delivery company Neos raised $25 million through the sale of 5 million shares at $5 in a follow-on underwritten by Cowen, BMO Capital Markets and JMP Securities. Neos Therapeutics Inc. (NASDAQ:NEOS),...
23:36 , Nov 22, 2016 |  BC Week In Review  |  Clinical News

Amphetamine XR oral suspension regulatory udpate

Neos submitted an NDA to FDA for NT-0201 to treat ADHD. The product is an oral suspension extended-release amphetamine polistirex using Neos’ dynamic time release suspension (DTRS) technology. Neos Therapeutics Inc. (NASDAQ:NEOS), Grand Prairie, Texas ...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Methylphenidate XR-ODT: Phase I data

Neos said a 3-way crossover Phase I bridging trial showed that a single dose of Cotempla XR-ODT met the primary and secondary endpoints for establishing bioequivalence under fasting conditions. Subjects received a commercial scale formulation...
07:00 , May 23, 2016 |  BC Week In Review  |  Company News

Neos Therapeutics sales and marketing update

Neos launched once-daily Adzenys XR-ODT amphetamine in the U.S. to treat ADHD in patients ages six and older. The wholesale acquisition cost (WAC) of a 3.1, 6.3, 9.4, 12.5, 15.7 or 18.8 mg tablet is...